Dr. Alexander Bondoc · Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study
Follow
Article1 min read·Published Mar 2024Older

Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Mar 2024 · 1 min read

In brief

In brief

Multi-institutional retrospective study of 78 pediatric patients with undifferentiated embryonal sarcoma of the liver treated across 17 North American centers over 30 years. Neoadjuvant chemotherapy achieved >90% tumor necrosis in most cases, with R0 resection being the key prognostic factor for event-free and overall survival.

Written by the GCMD Library team from the article.

Alexander Bondoc

Background: Undifferentiated embryonal sarcoma of the liver (UESL) is a rare tumor for which there are few evidence-based guidelines. The aim of this study was to define current management strategies and outcomes for these patients using a multi-institutional dataset curated by the Pediatric Surgical Oncology Research Collaborative. Methods: Data were collected retrospectively for patients with UESL treated across 17 children's hospitals in North America from 1989 to 2019. Factors analyzed included patient and tumor characteristics, PRETEXT group, operative details, and neoadjuvant/adjuvant regimens. Event-free and overall survival (EFS, OS) were the primary and secondary outcomes, respectively. Results: Seventy-eight patients were identified with a median age of 9.9 years [interquartile range [IQR): 7-12]. Twenty-seven patients underwent resection at diagnosis, and 47 patients underwent delayed resection, including eight liver transplants. Neoadjuvant chemotherapy led to a median change in maximum tumor diameter of 1.6 cm [IQR: 0.0-4.4] and greater than 90% tumor necrosis in 79% of the patients undergoing delayed resection. R0 resections were accomplished in 63 patients (81%). Univariate analysis found that metastatic disease impacted OS, and completeness of resection impacted both EFS and OS, while multivariate analysis revealed that R0 resection was associated with decreased expected hazards of experiencing an event [hazard ratio (HR): 0.14, 95% confidence interval (CI): 0

Statements in this article

  1. The median age at presentation for undifferentiated embryonal sarcoma of the liver is 9.9 years (interquartile range 7-12 years).

    ResearchResults
  2. Twenty-seven patients (35%) underwent resection at diagnosis while 47 patients (60%) underwent delayed resection after neoadjuvant chemotherapy.

    ResearchResults
  3. Eight patients underwent liver transplantation as part of their surgical management.

    ResearchResults
  4. Neoadjuvant chemotherapy led to a median change in maximum tumor diameter of 1.6 cm (interquartile range 0.0-4.4 cm).

    ResearchResults
  5. Greater than 90% tumor necrosis was achieved in 79% of patients undergoing delayed resection after neoadjuvant chemotherapy.

    ResearchResults
  6. R0 resections were accomplished in 63 patients (81% of the cohort).

    ResearchResults
  7. Metastatic disease at presentation impacts overall survival in univariate analysis.

    ResearchResults
  8. Completeness of resection impacts both event-free survival and overall survival in univariate analysis.

    ResearchResults
  9. R0 resection is associated with decreased expected hazards of experiencing an event (hazard ratio 0.14, 95% confidence interval 0.05-0.38) in multivariate analysis.

    ResearchResults

Read it at the source ↗

Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
Only a few other public items share this field — go deeper there →
GCMD Library — educational content from recorded physician discussions, not medical advice.